chalcone has been researched along with Parkinson Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Ding, L; Gong, J; Guo, W; Li, S; Xu, P; Zhang, M; Zhang, W; Zhang, Y | 1 |
| Gao, Y; Han, B; Hu, J; Lu, Y; Shen, J; Wang, T | 1 |
| Duan, SJ; Han, B; Lu, Y; Wang, LJ; Wang, SY; Wang, T; Zhu, Q | 1 |
3 other study(ies) available for chalcone and Parkinson Disease
| Article | Year |
|---|---|
Trojan Horse Delivery of 4,4'-Dimethoxychalcone for Parkinsonian Neuroprotection.
Topics: Animals; Blood-Brain Barrier; Chalcone; Disease Models, Animal; Drug Delivery Systems; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Substantia Nigra | 2021 |
Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Chalcone; Gene Expression Regulation, Enzymologic; Homovanillic Acid; Male; Neostriatum; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Quinones; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Tyrosine 3-Monooxygenase | 2013 |
Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Chalcone; Disease Models, Animal; Levodopa; Male; Motor Activity; Olfaction Disorders; Oxidopamine; Parkinson Disease; Quinones; Rats; Receptors, Dopamine D3; Time Factors | 2015 |